National News

Dr Kartik Chandulal Bhadra appointed as an Independent Director of IRCON

The Board of Directors of IRCON have approved the appointment of Dr Kartik Chandulal Bhadra as an Independent Director of IRCON Ltd

PSU Watch Bureau

New Delhi: Dr Kartik Chandulal Bhadra has been appointed as an Independent Director on the Board of Ircon International Limited (IRCON), a Miniratna PSU under the Ministry of Railways. The Board of Directors of IRCON in its meeting held on January 5, has approved the appointment of Dr Bhadra as an Independent (Part-Time Non-Official) Director (Additional Director) on the Board of the company with effect from December 31, 2021. This information has been shared by the Miniratna Railway PSU in a regulatory filing to the stock exchanges on Wednesday.

Dr Bhadra, aged 55 years, is an MBBS. He is a Paediatrician Doctor in Kalrav Children Hospital in Valsad, Gujarat since 1991. He is not related to any other Director of the company.

Ircon International Limited (IRCON) is an engineering and construction organisation, specialized in transport infrastructure. The PSU was established in 1976, by the government under the Indian Companies Act 1956. IRCON was registered as the Indian Railway Construction International Ltd., a wholly (100%) owned entity of the Ministry of Railways. Its primary charter was the construction of railway projects in India and abroad.

(PSU Watch– India's Business News centre that places the spotlight on PSUs, Bureaucracy, Defence and Public Policy is now on Google News. Click here to follow. Also, join PSU Watch Channel in your Telegram. You may also follow us on Twitter here and stay updated.)

Rupee strengthens against US dollar as foreign inflows, softer crude prices support sentiment

Sensex surges over 1,000 points, Nifty tops 25,300 as FII inflows, strong Q2 earnings fuel rally

Karnataka expects data centre demand to add another 1,000 MW in 4-5 years: Additional Chief Secretary

PESB recommends Jobi VP for CCL's Director (Personnel) post

Govt invites fresh applications under PLI scheme for medical devices; extends tenure till 2035-36